Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression

Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression

Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Acharya Balkrishna, Ritu Paliwal, Surjeet Singh, Rani Singh, Vivek Gohel, Rishabh Dev, Kunal Bhattacharya, Sandeep Sinha, Anurag Varshney
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Heliyon
Subjects:
Livogrit
Alpha-naphtylisothiocyanate
Cholestasis
Fibrosis
Inflammation
Ayurveda
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402500235X
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced cholestasis-like symptoms in male Sprague-Dawley rats. Livogrits's phytochemical profiling showed the presence of Gallic acid, Methyl Gallate, Catechin, Corilagin, Ellagic acid, Rutin, and Cinnamic acid. Sprague-Dawley rats were pre-treated with Livogrit (20–600 mg/kg/day) and reference drug Ursodeoxycholic acid (100 mg/kg/day) for 15 and 5 days, respectively, before single-dose ANIT (100 mg/kg) stimulation. Livogrit treatment protect the rats against ANIT-induced increase in blood serum markers (total bile acids, ALT, AST, GGT, ALP, total cholesterol, and total bilirubin) and reduced manifestation of liver necrosis, inflammation, and periportal fibrosis. At molecular level, Livogrit inhibited up-regulation of BAX, TGF-β, α-SMA, and MMP-9 mRNA expressions, associated with the liver damages. Taken together, this study supported Livogrit's potential as hepatoprotective medicine against cholestasis-like-etiologies.
ISSN:2405-8440

Similar Items